Hydrophobic substituents on isatin derivatives enhance their inhibition against bacterial peptidoglycan glycosyltransferase activity
- PMID: 32146179
- DOI: 10.1016/j.bioorg.2020.103710
Hydrophobic substituents on isatin derivatives enhance their inhibition against bacterial peptidoglycan glycosyltransferase activity
Abstract
Moenomycin A, the well-known natural product inhibitor of peptidoglycan glycosyltransferase (PGT), is a large amphiphilic molecule of molecular mass of 1583 g/mol and its bioavailablity as a drug is relatively poor. In searching for small-molecule ligands with high inhibition ability targeting the enzyme, we found that the addition of hydrophobic groups to an isatin-based inhibitor of bacterial PGT significantly improves its inhibition against the enzyme, as well as its antibacterial activity. The improvement in enzymatic inhibition can be attributed to a better binding of the small molecule inhibitor to the hydrophobic region of the membrane-bound bacterial cell wall synthesis enzyme and the plasma membrane. In the present study, a total of 20 new amphiphilic compounds were systematically designed and the relationship between molecular hydrophobicity and the antibacterial activity by targeting at PGT was demonstrated. The in vitro lipid II transglycosylation inhibitory effects (IC50) against E. coli PBP1b and MICs of the compounds were investigated. Optimized results including MIC values of 6 μg/mL for MSSA, MRSA, B. subtilis and 12 μg/mL for E. coli were obtained with an isatin derivative 5m which has a molecular mass of 335 g/mol.
Keywords: Antimicrobial; Hydrophobicity; Inhibitors; Peptidoglycan glycosyltransferase.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Rational structural modification of the isatin scaffold to develop new and potent antimicrobial agents targeting bacterial peptidoglycan glycosyltransferase.RSC Adv. 2021 May 19;11(29):18122-18130. doi: 10.1039/d1ra02119b. eCollection 2021 May 13. RSC Adv. 2021. PMID: 35480164 Free PMC article.
-
Structure-based design, synthesis, and biological evaluation of isatin derivatives as potential glycosyltransferase inhibitors.Chem Biol Drug Des. 2014 Dec;84(6):685-96. doi: 10.1111/cbdd.12361. Epub 2014 Aug 14. Chem Biol Drug Des. 2014. PMID: 24890564
-
Targeting the forgotten transglycosylases.Biochem Pharmacol. 2006 Mar 30;71(7):957-67. doi: 10.1016/j.bcp.2005.10.030. Epub 2005 Nov 18. Biochem Pharmacol. 2006. PMID: 16298347 Review.
-
Targeting Bacterial Cell Wall Peptidoglycan Synthesis by Inhibition of Glycosyltransferase Activity.Chem Biol Drug Des. 2016 Feb;87(2):190-9. doi: 10.1111/cbdd.12662. Epub 2015 Oct 9. Chem Biol Drug Des. 2016. PMID: 26358369
-
The molecular biology of moenomycins: towards novel antibiotics based on inhibition of bacterial peptidoglycan glycosyltransferases.Biol Chem. 2010 May;391(5):499-504. doi: 10.1515/BC.2010.053. Biol Chem. 2010. PMID: 20302515 Review.
Cited by
-
Rational structural modification of the isatin scaffold to develop new and potent antimicrobial agents targeting bacterial peptidoglycan glycosyltransferase.RSC Adv. 2021 May 19;11(29):18122-18130. doi: 10.1039/d1ra02119b. eCollection 2021 May 13. RSC Adv. 2021. PMID: 35480164 Free PMC article.
-
A Mini Review on Isatin, an Anticancer Scaffold with Potential Activities against Neglected Tropical Diseases (NTDs).Pharmaceuticals (Basel). 2022 Apr 27;15(5):536. doi: 10.3390/ph15050536. Pharmaceuticals (Basel). 2022. PMID: 35631362 Free PMC article. Review.
-
Structural diversity, bioactivity, and biosynthesis of phosphoglycolipid family antibiotics: Recent advances.BBA Adv. 2022 Nov 17;2:100065. doi: 10.1016/j.bbadva.2022.100065. eCollection 2022. BBA Adv. 2022. PMID: 37082588 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical